Chronic Telogen Effluvium
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy of Neosil in the treatment of chronic effluvium
Interventions
DRUGNeosil complete
Oral, during 24 weeks.
DRUGPantogar
Oral, placebo for 12 weeks and pantogar for 12 weeks.
DRUGNeosil
Oral, during only 12 weeks.
Sponsors
Luxbiotech
EMS
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants who present hair loss for more than 6 months; * Do not use other possible cosmetic or dermatological treatments, during the trial; * Not change the diet during the trial and not be any restrictive diet during this period.
Exclusion criteria
* Pregnancy or risk of pregnancy and lactating patients; * Use of any products to promote hair growth within the 6 months prior to the Baseline Visit; * History of hair transplants; * Current skin disease; * History hypersensitivity to the active ingredients used in the study; * Participation in clinical trial in the year prior to this study; * Known history of non controled systemic disease (diabetes, hypertension, anemia, iron deficiency, and others); * Gastric diseases; * Smoker; * History of systemic disease (HIV, non specify autoimmune disease, hepatitis, and others).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hair density | 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and severity of adverse events recorded during the study | 24 weeks |
Countries
Brazil
Outcome results
None listed